BioRestorative Therapies Stock Forecast

BRTX's stock price has decreased by -76.1% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 2 analysts polled by S&P Global, BioRestorative Therapies stock has a consensus rating of "Buy" and an average price target of $8.00. The average 1-year stock price forecast is 1,887.08% higher than the current stock price, while the lowest is $1.00 (+148.39%) and the highest is $15 (+3,625.78%).

Price Target: $8.00 (+1,887.08%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.00	$8.00	$8.00	$15
Change	+148.39%	+1887.1%	+1887.1%	+3625.8%

* Price targets were last updated on Apr 9, 2026.

Analyst Ratings

The average analyst rating for BioRestorative Therapies stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	May '25	Jun '25	Aug '25	Nov '25	Feb '26	Apr '26
Strong Buy	1	1	1	1	1	1
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Okunewitch Maxim Group	Maxim Group	Buy Maintains $1	Buy	Maintains	$1	+148.39%	Apr 9, 2026
Jonathan Aschoff Roth MKM	Roth MKM	Buy Maintains $18 → $15	Buy	Maintains	$18 → $15	+3,625.78%	Apr 2, 2026

Financial Forecast

Revenue This Year

1.41M

from 359.70K

290.60%

from 359.70K

Revenue Next Year

2.31M

from 1.41M

64.59%

from 1.41M

EPS This Year

-0.66

from -1.58

EPS Next Year

-0.52

from -0.66

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	46.00K	119.80K	145.80K	401.00K	359.70K	1.41M
Revenue Growth	-40.26%	160.44%	21.70%	175.03%	-10.30%	290.60%
Gross Profit	46.00K	119.80K	145.80K	372.93K	335.86K	1.33M
Gross Margin	100.00%	100.00%	100.00%	93.00%	93.37%	95.00%
Operating Income	-26.31M	-18.97M	-15.22M	-11.56M	-15.65M	-13.61M
Net Income	-44.30M	-13.22M	-10.42M	-8.98M	-14.24M	-13.52M
EPS	-	-	-	-	-1.58	-0.66
Free Cash Flow	5.70M	6.15M	-5.08M	-3.11M	-6.20M	-37.92M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	2.5M
Avg	1.4M
Low	310,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	595.0%
Avg	290.6%
Low	-13.8%

EPS Forecast

EPS	2026	2027	2028
High	-0.66
Avg	-0.66
Low	-0.66

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-